Neurology Book

//fpnotebook.com/

Sugammadex

Aka: Sugammadex, Bridion
  1. Indications
    1. Rapid reversal of Rocuronium and Vecuronium
    2. FDA approved for reversal in adult surgery cases, to speed recovery after case completion
    3. Emergency reversal is off-label use (can't intubate - can't ventilate, neurologic injury assessment)
  2. Background
    1. Approved in Europe in 2008
    2. FDA approved in U.S. in 2016 (initially rejected due to Anaphylaxis risk)
  3. Mechanism
    1. Sugammadex tightly binds Rocuronium and Vecuronium
    2. Prevents paralytic binding to acetylcholine receptors
  4. Pharmacokinetics
    1. Reverses paralysis within 3 minutes
  5. Dosing
    1. Typical dose: 4 mg/kg total body weight
    2. Rapid reversal dose: 16 mg/kg total body weight
  6. Adverse Effects
    1. Anaphylaxis in 0.3% of patients
    2. Bradycardia
  7. References
    1. Braude and Hayes in Herbert (2016) EM:Rap 16(11): 7

Sugammadex (C1700695)

Concepts Pharmacologic Substance (T121) , Carbohydrate (T118)
MSH C453980
SnomedCT 442379000, 442340006
English Sugammadex (product), Sugammadex (substance), Sugammadex, sugammadex, SUGAMMADEX
Spanish sugammadex, sugammadex (sustancia), sugammadex (producto)
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Bridion (C2699711)

Concepts Pharmacologic Substance (T121)
English Bridion
Sources
Derived from the NIH UMLS (Unified Medical Language System)


You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree